Zone 2 锚定区医生改良开窗 TEVAR 的长期结局
本研究回顾性分析 41 例需 Zone 2 锚定并重建左锁骨下动脉的患者,采用 Lifetech Ankura 胸主动脉支架行医生改良开窗 TEVAR。技术成功率 100%,随访 51.9±13.6 个月,LSA 原发/继发通畅率 100%/97.6%,无主动脉相关死亡,2 例 1a 型内漏经 TEVAR 加颈锁旁路处理。
要点
- 医生改良开窗 TEVAR 在 Zone 2 锚定区技术成功率高,LSA 通畅率良好。
- 随访中无主动脉相关死亡,1a 型内漏发生率低且可经 TEVAR 加颈锁旁路处理。
- 小样本、异质性病理和晚期事件少限制结论,需更大对比研究验证耐久性。
核心结论
- 医生改良开窗 TEVAR 使用 Lifetech Ankura 胸主动脉支架在 Zone 2 锚定区可行,技术成功率高,LSA 通畅率良好,随访结局令人鼓舞。
研究设计与样本
- 回顾性单中心系列,纳入 2020 年 1 月至 2026 年 1 月 41 例需 Zone 2 锚定并 LSA 重建的胸主动脉病变患者,使用 Lifetech Ankura 胸主动脉支架行医生改良开窗 TEVAR,改良时未使用加固缝线。
主要发现
- 患者平均年龄 58.2±11.2 岁(34-85 岁),无中转开放手术,技术成功率 100%。
- 8 例(19.5%)行 LSA 选择性原发球囊扩张支架置入以优化分支通畅,9 例(21.95%)在急诊条件下手术。
- ICU 平均 14.8±7.1 小时(4-36 小时),住院平均 3.8±1.4 天(3-6 天),开窗操作平均 11.3±3.2 分钟(8-18 分钟),透视平均 9.2±4.3 分钟(4-22 分钟)。
- 随访 51.9±13.6 个月(5-66 个月),LSA 原发和继发通畅率分别为 100% 和 97.6%。
- 2 例发生 1a 型内漏,分别在第 12 和 18 个月行 TEVAR 加颈锁旁路;1 例第 28 个月因心脏原因死亡;无主动脉相关死亡。
临床怎么用
- 对于需 Zone 2 锚定并 LSA 重建的胸主动脉病变,医生改良开窗 TEVAR 可作为克服定制支架制造延迟、高费用和解剖限制的可行选择。
- 术中可选择性行 LSA 球囊扩张支架置入以优化分支通畅,术后需长期随访监测内漏和 LSA 通畅性。
局限性
- 样本量小(41 例),病理异质性大,晚期事件数量有限,需更大规模对比研究以明确耐久性和病理特异性表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgeon-modified fenestrated stent grafts (SMFSGs) have emerged to overcome limitations related to manufacturing delays, high procedural costs, anatomical constraints, and limited availability of custom-made branched or fenestrated endografts. The aim of this study was to evaluate the safety, feasibility, and mid- to long-term follow-up outcomes of the SMFSG technique for zone 2 landing using the Lifetech Ankura™ thoracic endograft. METHODS: Between January 2020 and January 2026, 41 consecutive patients with thoracic aortic pathology requiring zone 2 landing and left subclavian artery (LSA) revascularization using SMFSG with the Lifetech Ankura thoracic endograft (Lifetech Scientific, Shenzhen, China) were included in the study. No reinforcement sutures were used during graft modification. The primary and secondary endpoints were overall mortality and aorta-related mortality (ARM), endoleak, patency of LSA, and reinterventions in the follow-up period. RESULTS: The mean age of the patient cohort was 58.2 ± 11.2 (34-85) years. There was no open conversion to surgery, and technical success was 100% according to the study definition. Eight patients (19.5%) underwent selective primary balloon-expandable stent placement in the LSA to optimize branch patency. Nine patients (21.95%) underwent the procedure under emergency conditions. The mean intensive care unit period was 14.8 ± 7.1 hours (4-36 hours). The mean length of stay was 3.8 ± 1.4 days (3-6 days). The fenestration procedure took a mean period of 11.3 ± 3.2 minutes (8-18 minutes). The fluoroscopy period was 9.2 ± 4.3 minutes (4-22 minutes). The follow-up period was 51.9 ± 13.6 months (5-66 months). Primary and secondary LSA patency rates were 100% and 97.6% for the follow-up period. Two patients experienced type 1a endoleak, and both had thoracic endovascular aortic repair (TEVAR) and carotid-subclavian bypass at the 12th and 18th month. One patient died at the 28th month due to cardiac causes. There was no ARM. CONCLUSION: In this retrospective single-center series, surgeon-modified fenestrated TEVAR using the Lifetech Ankura thoracic endograft was feasible and achieved high technical success with favorable LSA patency and encouraging follow-up outcomes. However, interpretation is limited by the small sample size, heterogeneous pathology, and limited number of late events. Larger comparative studies are needed to better define durability and pathology-specific performance.
引用
- Zafer Iscan H, Bogachan Akkaya B, Kulahcioglu E, et al. Long-Term Outcomes of Surgeon-Modified Fenestrated TEVAR at Zone 2 Landing. Ann Vasc Surg. 2026. PMID: 42297348. doi:10.1016/j.avsg.2026.05.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。